Anokion
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Epfl Innovation Park-l 1a, Ecublens, Vau...Phone Number
(857) 320-6607Website
www.anokion.comRevenue
$10.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Anokion
Anokion US, Inc. specializes in enhancing the treatment and prognosis of autoimmune diseases through its proprietary antigen-specific immune tolerance technology, surpassing conventional standards of care in effectiveness and specificity. The company applies its innovative approach to diminish the immunogenicity of therapeutic proteins and combat autoimmune and allergic conditions. With its platform technology, Anokion's antigen-specific tolerance strategy can be adapted to diverse proteins across various clinical applications.Explore more
Anokion Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Anokion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Anokion
Product Launch: Get notified when Anokion launches new products
Check if Anokion has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Anokion recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Anokion is spiking on competitors!
Anokion, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Anokion had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Anokion has new funding data
Recommended Actions
Reach out to Masked Content who joined Anokion as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Anokion is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Anokion is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Anokion.
Anokion financials insights
Gather financial insights about Anokion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$40M
2022
Private Equity
$35M
Anokion Tech Stack
A closer look at the technologies used by Anokion
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Event
Events
Promotion
Executive Move
Executive Moves, Promotion
New Hire
Executive Move
Executive Moves, New Hire
Anokion News & Media
Anokion Announces the Early Completion of Enrollment in the ACeD-it Phase 2 and the SynCeD Phase 2a Trials of KAN-101 for the Treatment of Celiac Disease
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the early completion of patient dosing in the Phase 2 ACeD-it and Phase 2a SynCeD trials of KAN-101, a potential disease-modifying treatment for celiac disease. Topline data from both the Phase 2 ACeD-it and Phase 2a SynCeD clinical trials are expected in the first half of 2025. KAN-101 is a novAnokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced data will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) being held September 18-20, 2024 in Copenhagen, Denmark. The abstracts include pre-clinical and new clinical data from Anokion’s Phase 1 MoveS-it study evaluating theAnokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced additional favorable safety and efficacy data from the company’s ongoing Phase 1b/2 clinical trial (ACeD-it) evaluating KAN-101 as a treatment for celiac disease. The findings were presented on Sunday, May 19, 2024 in an oral presentation titled “Assessment of KAN-101 in CeD and Immune ToleranceAnokion to Participate in BofA Healthcare Trailblazers Conference
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass. About Anokion Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meanin
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anokion
Sign Up For FreeTo access detailed company insights
Anokion US, Inc. specializes in enhancing the treatment and prognosis of autoimmune diseases through its proprietary antigen-specific immune tolerance technology, surpassing conventional standards of care in effectiveness and specificity. The company applies its innovative approach to diminish the immunogenicity of therapeutic proteins and combat a... Read More
